UNI-MB - logo
UMNIK - logo
 
E-viri
Celotno besedilo
Recenzirano Odprti dostop
  • Case report: EML4::NTRK3 ge...
    Lazzari, Chiara; Pecciarini, Lorenza; Doglioni, Claudio; Pedica, Federica; Gajate, Ana Maria Samanes; Bulotta, Alessandra; Gregorc, Vanesa; Cangi, Maria Giulia

    Frontiers in oncology, 11/2022, Letnik: 12
    Journal Article

    Rearrangements involving the neurotrophin kinase ( NTRK ) genes NTRK1 , NTRK2 and NTRK3 with different fusion partners have been observed in both adult and pediatric solid tumors. Larotrectinib and entrectinib have been the first tumor-agnostic compounds approved for the treatment of NTRK fusion-positive tumors. Here, we report the first case of a female patient with a diagnosis of stage IV lung adenocarcinoma harboring the EML4::NTRK3 gene fusion, and successfully treated with entrectinib.